Frontiers in Endocrinology (Dec 2021)

Corrigendum: Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial

  • Chengjun Sun,
  • Biao Lu,
  • Yu Liu,
  • Yaqin Zhang,
  • Haiyan Wei,
  • Xu Hu,
  • Pei Hu,
  • Qian Zhao,
  • Yanling Liu,
  • Kan Ye,
  • Kan Wang,
  • Zaiyan Gu,
  • Zheng Liu,
  • Jin Ye,
  • Hongxiao Zhang,
  • Hong Zhu,
  • Zhihong Jiang,
  • Yanjie Liu,
  • Naijun Wan,
  • Chengming Yan,
  • Jianying Yin,
  • Lirong Ying,
  • Feng Huang,
  • Qingjin Yin,
  • Li Xi,
  • Feihong Luo,
  • Ruoqian Cheng

DOI
https://doi.org/10.3389/fendo.2021.830469
Journal volume & issue
Vol. 12

Abstract

Read online

No abstracts available.

Keywords